Englander Institute creates big data solution

Monday, July 11, 2016

One of the biggest challenges in precision medicine is what to do with the mountain of data generated from the sequencing of each tumor – how to parse out the relevant information and make it accessible and useful to the physicians making treatment decisions. 

The Englander Institute for Precision Medicine (IPM) tackled the first hurdle by creating simple-to-read “tumor profiles,” and now it has made another leap by making this data available in Weill Cornell Medicine’s electronic record in a format readily available for Clinical Decision Support, a function defined by the Federal Office of the National Coordinator for Health Information Technology as “knowledge and person-specific information, intelligently filtered or presented at appropriate times, to enhance health and health care..

The technical feat was achieved during the spring, when a cross-institutional team of clinical IT staff and computational biologists from several departments at Weill Cornell Medicine along with Standard Molecular, Inc. successfully linked IPM reports into the Epic electronic medical record (EMR) management system in use by Weill Cornell Physicians in a highly detailed, computer-readable format.

"Integrating a chunk of text and an image of a genomics report in an electronic record has been the existing practice. This level of integrating rich discretely detailed genomics data into medical records was a longstanding technical challenge, which we have now solved,” said David Artz, M.D., Associate Professor of Healthcare Policy and Research (Courtesy) at Weill Cornell Medicine and Chief Medical Officer of Standard Molecular.            

“This will enable doctors and researchers alike to be able to directly compare lab results with clinical data, which will enhance our ability to truly tailor the care of each patient,” said Mark Rubin, M.D., Director of the Englander Institute for Precision Medicine.

Artz expects the system will be rolled out for doctors’ use in January.  As part of the system, physicians will also be able to set up alerts so they can be notified if a patient’s molecular profile matches specific clinical trial enrollment criteria. 

“Since many novel treatments are directed toward molecular targets rather than individual disease subtypes, ready access to this information will be very helpful to clinicians who wish to offer appropriate clinical trials to their patients,” said John Leonard, M.D., the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Associate Director of Clinical Trials at the Meyer Cancer Center.

Successful precision medicine relies on breaking down data silos allowing for broader usage of genetic information in making patient care and treatment decisions, and greater access to additional treatment options through clinical trials. The Englander Institute has created a system that improves Clinical Decision Support - the next challenge is bridging the gap for such information to be shared securely with other institutions, Artz said.

“This project could advance the field of precision medicine beyond Weill Cornell,” he added.  "We’ve created a model for how it could be used elsewhere, especially at other institutions that use Epic."

Related Stories

Weill Cornell uses HL7 to help integrate structured genomic data into Epic EHR

API-based genomics databank facilitates personalized medicine

Three-pronged approach key to precision medicine

Weill Cornell will help lead national precision medicine effort

Weill Cornell Medicine to expand tumor exome test to thousands of advanced cancer patients

Sift, Sort, Seize Transcriptomic Gold

Advantages with Whole-Exome Sequencing

Weill Cornell team publishes details of precision medicine knowledgebase of somatic tumor mutations

How precision medicine will shift from research to clinical care

A new paradigm: Precision medicine

Genomic data sharing expands possibilities of precision medicine

Cancer and big data analytics

Big Data Key to Precision Medicine's Success

Changes in cancer epigenome implicated in chemotherapy resistance and lymphoma relapse

New layer of gene regulation may play key role in common lymphoma

New study describes genomic landscape of castration-resistant prostate cancer

New tool predicts drug targets and IDs new anticancer compounds

Batting it out of the park

Precision medicine testing options expand with approval of EXaCT-1 test

Researchers validate precision medicine approach using new whole exome sequencing test

Precision Medicine: Working Toward Custom-Fitted Cures

The new style of tailored treatment

Gift Names Caryl and Israel Englander Institute for Precision Medicine

Fine-Combing the Cancer Transcriptome

Big Data and Bacteria: Mapping the New York Subway’s DNA

Privacy in the post-genomic era: Impossible